Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker DNTH
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Vanguard Capital Management | 2.85M | 5.1% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Alex Silverstein | 1.70M | 3.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Sirenia Capital Management LP | 1.70M | 3.1% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Wellington Management Company LLP | 3.23M | 5.5% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Wellington Investment Advisors Holdings LLP | 3.23M | 5.9% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Wellington Group Holdings LLP | 3.23M | 5.9% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Wellington Management Group LLP | 3.23M | 5.9% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | T. Rowe Price Investment Management, Inc. | 6.63M | 12.1% | SCHEDULE 13G/A ↗ |
| Aug 7, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | T. Rowe Price Investment Management, Inc. | 3.89M | 7.1% | SCHEDULE 13G ↗ |
| Jul 28, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | BlackRock, Inc. | 3.50M | 6.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 2.61M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Rajeev Shah | 2.61M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Peter Kolchinsky | 2.61M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | RA Capital Management, L.P. | 2.61M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Steven A. Cohen | 643,599 | 1.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 643,599 | 1.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Point72 Asset Management, L.P. | 643,599 | 1.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Alex Silverstein | 2.80M | 5.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | Sirenia Capital Management LP | 2.80M | 5.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Wellington Investment Advisors Holdings LLP | 2.60M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Wellington Group Holdings LLP | 2.60M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Wellington Management Group LLP | 2.60M | 4.8% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Ting Jia | 1.95M | 3.6% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Octagon Biotech Opportunities Fund I LP | 291,667 | 0.6% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Octagon Investments Master Fund LP | 1.66M | 3.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Octagon Capital Advisors LP | 1.95M | 3.6% | SCHEDULE 13G/A ↗ |
| Apr 27, 2026 | SCHEDULE 13G | DNTH Dianthus Therapeutics, Inc. | BlackRock, Inc. | 2.63M | 5.1% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 2.61M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Rajeev Shah | 2.61M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Peter Kolchinsky | 2.61M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | RA Capital Management, L.P. | 2.61M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Steven A. Cohen | 2.98M | 6.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 2.98M | 6.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Point72 Asset Management, L.P. | 2.98M | 6.9% | SCHEDULE 13G/A ↗ |
| Nov 25, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Tomas Kiselak | 2.14M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 25, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Peter Evan Harwin | 2.14M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 25, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Fairmount Healthcare Fund II L.P. | 2.14M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 25, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Fairmount Funds Management LLC | 2.14M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Michael Gregory | 2.10M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Avidity Private Master Fund I LP | 1.90M | 4.4% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Avidity Capital Partners (GP) LLC | 2.10M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Avidity Capital Partners Fund (GP) LP | 2.10M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Avidity Partners Management (GP) LLC | 2.10M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | DNTH Dianthus Therapeutics, Inc. | Avidity Partners Management LP | 2.10M | 4.9% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 3.87M | 9.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Rajeev Shah | 3.87M | 9.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Peter Kolchinsky | 3.87M | 9.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | RA Capital Management, L.P. | 3.87M | 9.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Ting Jia | 2.42M | 6.1% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | DNTH Dianthus Therapeutics, Inc. | Octagon Private Opportunities Fund II LP | 291,667 | 0.7% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances